X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
FULFORD (INDIA) LIMITED Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

FULFORD (INDIA) LIMITED  (FLFD)


Here is the latest financial fact sheet of Fulford India. For more details, see the Fulford India quarterly results and Fulford India share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
fulford india - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 2,362.0       No. of shares m 3.90
    Mkt Cap Rs m 9,212       % ch % 0.0
    Vol '000 3.3       % ch week % 0.9
    P/E X 398.8       % ch 1-mth % 5.3
    P/CF X 153.8       % ch 12-mth % 44.0
    EPS (TTM) Rs 5.9       52 week H/L Rs 2,365.0/1,100.0
(As on Jul 30, 2015 (Close)) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Dec-09
*
12
Dec-10
*
12
Dec-11
*
12
Dec-12
*
15
Mar-14
*
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs8441,2731,064958942 
Low Rs272787389452450 
Sales per share (Unadj.) Rs471.5487.7549.2552.2691.4 
Earnings per share (Unadj.) Rs34.530.94.7-12.811.5 
Diluted earnings per shareRs34.530.94.7-12.811.5 
Cash flow per share (Unadj.) Rs37.335.09.1-8.415.4 
Dividends per share (Unadj.) Rs4.504.503.501.002.00 
Adj. dividends per shareRs4.504.503.501.002.00 
Dividend yield (eoy) %0.80.40.50.10.3 
Book value per share (Unadj.) Rs358.6384.2384.9370.9380.0 
Adj. book value per shareRs358.6384.2384.9370.9380.0 
Shares outstanding (eoy) m3.903.903.903.903.90 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x1.22.11.31.31.0 
Avg P/E ratio x16.233.3154.0-55.160.7 
P/CF ratio (eoy) x15.029.579.8-83.645.3 
Price / Book Value ratio x1.62.71.91.91.8 
Dividend payout %13.014.674.2-7.817.4 
Avg Mkt Cap Rs m2,1764,0182,8332,7502,714 
No. of employees `0000.40.50.50.50.4 
Total wages/salary Rs m286332420451505 
Avg. sales/employee Rs Th4,132.63,850.24,284.04,524.66,073.0 
Avg. wages/employee Rs Th642.2671.5839.0947.31,137.4 
Avg. net profit/employee Rs Th302.7243.936.8-104.8100.7 
  INCOME DATA
Net Sales Rs m1,8391,9022,1422,1542,696 
Other income Rs m68799497125 
Total revenues Rs m1,9071,9812,2362,2502,822 
Gross profit Rs m166114-49-152-46 
Depreciation Rs m1116171715 
Interest Rs m031010 
Profit before tax Rs m22317427-7354 
Minority Interest Rs m00000 
Prior Period Items Rs m-20000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m86539-2310 
Profit after tax Rs m13512118-5045 
Gross profit margin %9.06.0-2.3-7.0-1.7 
Effective tax rate %38.630.731.931.217.7 
Net profit margin %7.36.30.9-2.31.7 
  BALANCE SHEET DATA
Current assets Rs m1,5481,8411,9201,7251,738 
Current liabilities Rs m367424616513545 
Net working cap to sales %64.274.560.956.244.3 
Current ratio x4.24.33.13.43.2 
Inventory Days Days7163767648 
Debtors Days Days292216114 
Net fixed assets Rs m5655422712 
Share capital Rs m3939393939 
"Free" reserves Rs m1,3591,4591,4621,4081,443 
Net worth Rs m1,3981,4991,5011,4471,482 
Long term debt Rs m00000 
Total assets Rs m1,7661,9232,1622,0092,077 
Interest coverage xNM61.039.6-180.36.7 
Debt to equity ratio x00000 
Sales to assets ratio x1.01.01.01.11.3 
Return on assets %7.66.40.9-2.52.6 
Return on equity %9.68.01.2-3.43.0 
Return on capital %15.811.81.8-5.04.3 
Exports to sales %00000 
Imports to sales %36.628.536.532.924.5 
Exports (fob) Rs m00000 
Imports (cif) Rs m673542781708659 
Fx inflow Rs m001917 
Fx outflow Rs m1,097558812727673 
Net fx Rs m-1,097-558-811-718-656 
  CASH FLOW
From Operations Rs m -45 60 112 -266 90 
From Investments Rs m 7 180 78 85 105 
From Financial Activity Rs m -9 -23 -21 -16 -14 
Net Cashflow Rs m -47 216 169 -198 181 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for fulford (india) limited

 Raw Materials Data
Top
ITEM Rs m % To R.M.C. % To SALES
Antibiotics 20.0 89.3 0.7
Others 2.4 10.7 0.1

 Share Holding
Indian Promoters : 0.0%
Foreign collaborators : 75.0%
Indian inst/Mut Fund : 3.8%
FIIs : 0.1%
ADR/GDR : 0.0%
Free float : 21.2%
Shareholders : 4,783
Pledged promoter(s) holding : 0.0%
 Company Information
Top
    REGD OFF: Platina, 8th Floor, Plot No. C-59, G-Block, B. K. C, Bandra (E), Mumbai-400 098
    E-MAIL: sachin.gaikwad@merck.com     WEB: www.fulfordindia.com
    TELEPHONE: (022) 6789 8888     FAX: (022) 6789 8889
    SECTOR: PHARMACEUTICALS     GROUP: M N C
    TR AGENT: Link Intime India, C13, Pannalal Silk Mills Compd., LBS Marg, Mumbai-78
    AUDITOR: Lovelock & Lewes
CHM: Ajit Dangi COMP SEC: Sachin A. Gaikwad YEAR OF INC: 1948 BSE CODE: 506803 FV (Rs): 10 DIV YIELD (%): 0.1

More pharmaceuticals Company Fact Sheets:   DIVIS LABORATORIESCADILA HEALTHCAREWYETH LTDGLENMARK PHARMABIOCON LTD


Today's Market

Negative Finish to the Week; FMCG & Realty Stocks Fall(Closing)

Indian share markets retreated in today's trade from record highs hit earlier this week as investors booked profits ahead of a long weekend.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Our Private Class with India's Value Investing Guru(The 5 Minute Wrapup)

Apr 19, 2017

Rohan and Kunal present you the discussions with professor Sanjay Bakshi in his virtual classroom.

HDFC Bank: The Solid Outperformer(Chart Of The Day)

Apr 22, 2017

Why HDFC Bank beat the Sensex by nearly 3 times.

We Don't Want More F&O Stocks... We Need Smaller Lot Sizes(Daily Profit Hunter)

Apr 26, 2017

Are you excited to trade in the sixteen new stocks to be introduced in the F&O segment this Friday?

In an Ocean of Corporate Defaulters, Vijay Mallya is a Small Fish(Vivek Kaul's Diary)

Apr 20, 2017

While it is important to get Mallya back to India, the government needs to show the same vigour in chasing defaulters of public sector bank loans residing in India.

4 Ways GST Will Impact The Mutual Fund Industry(Outside View)

Apr 19, 2017

PersonalFN explains how GST would impact India's mutual fund industry and investors

More

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FULFORD INDIA

FULFORD INDIA - TEVA PHARMA COMPARISON

Compare Company With Charts

COMPARE FULFORD INDIA WITH

MARKET STATS